HomeCompareCHSYF vs JNJ

CHSYF vs JNJ: Dividend Comparison 2026

CHSYF yields 2.81% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $9.1K in total portfolio value· pulled ahead in Year 7
10 years
CHSYF
CHSYF
● Live price
2.81%
Share price
$1.35
Annual div
$0.04
5Y div CAGR
-21.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.2K
Annual income
$27.60
Full CHSYF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — CHSYF vs JNJ

📍 JNJ pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCHSYFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CHSYF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CHSYF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CHSYF
Annual income on $10K today (after 15% tax)
$239.26/yr
After 10yr DRIP, annual income (after tax)
$23.46/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,962.53/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CHSYF + JNJ for your $10,000?

CHSYF: 50%JNJ: 50%
100% JNJ50/50100% CHSYF
Portfolio after 10yr
$25.7K
Annual income
$2,358.50/yr
Blended yield
9.17%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

CHSYF
No analyst data
Altman Z
10.1
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CHSYF buys
0
JNJ buys
0
No recent congressional trades found for CHSYF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCHSYFJNJ
Forward yield2.81%2.13%
Annual dividend / share$0.04$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-21.3%28%
Portfolio after 10y$21.2K$30.3K
Annual income after 10y$27.60$4,689.40
Total dividends collected$979.00$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CHSYF vs JNJ ($10,000, DRIP)

YearCHSYF PortfolioCHSYF Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,922$221.53$10,592$272.30+$330.00CHSYF
2$11,864$177.95$11,289$357.73+$575.00CHSYF
3$12,837$142.18$12,123$472.89+$714.00CHSYF
4$13,848$113.15$13,141$629.86+$707.00CHSYF
5$14,908$89.78$14,408$846.81+$500.00CHSYF
6$16,022$71.09$16,021$1,151.60+$1.00CHSYF
7← crossover$17,200$56.19$18,122$1,588.22$922.00JNJ
8$18,448$44.37$20,930$2,228.20$2.5KJNJ
9$19,775$35.00$24,792$3,191.91$5.0KJNJ
10$21,186$27.60$30,274$4,689.40$9.1KJNJ

CHSYF vs JNJ: Complete Analysis 2026

CHSYFStock

China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. The company's products include Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu for the treatment of acute heart failure; Deanxit for the treating mild-to-moderate depression, anxiety, and psychosomatic affections; Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis; Salofalk for treating Ulcerative Colitis and Crohn's disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar. Its products also comprise DanShenTong capsules for treating acne, tonsillitis, otitis externa, boils, carbuncle, traumatic infection, burn infection, mastitis, cellulitis, osteomyelitis, etc.; XiDaKang, a protein hydrolysate oral solution; YiNuoShu for treating respiratory diseases; Ganfule capsules for the treatment of primary cancer of the liver; Imdur for the treatment of coronary heart disease, chronic heart failure, and myocardial infarction, as well as for prevention of vasospasm and mixed angina; and Parlodel tablets for the endocrine and neuro system indications. In addition, the company also offers Elcatonin injection for osteoporosis; YinlianQinggan granules for treating acute hepatitis A and chronic hepatitis B; Lamisil tablets for treating fungal infections on skin and hair; and MOVICOL for treating chronic constipation and faecal impaction. In addition, it is involved in the agriculture and livestock activities. The company was founded in 1995 and is headquartered in North Point, Hong Kong. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited.

Full CHSYF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this CHSYF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CHSYF vs SCHDCHSYF vs JEPICHSYF vs OCHSYF vs KOCHSYF vs MAINCHSYF vs ABBVCHSYF vs MRKCHSYF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.